What the FDA Actually Cleared When UpDoc Became the First Patient-Facir LLM Medical Device: A Stanford Insuli Titration Trial, a Drug-Dose-Calculato Predicate, and the Real Shape of Clinical AI

JUN 29, 2026 • PAID

1

Video Preview

Could not load video.

🎧 Podcast episode for paid subscriber only. Also available on Spotify.

Thoughts on Healthcare Markets & Technology

🎧 **What the FDA Actually Cleared When UpDoc Became the First Patient-Facing LLM Medical Device: A Stanford Insulin-Titration Trial, a Drug-Dose-Calculator Predicate, and the Real Shape of Clinical AI**

The FDA just cleared the first patient-facing LLM medical device. The headline says it redefined clinical AI. The actual clearance file tells a more interesting story…

Listen now

4 hours ago · Thoughts on Healthcare

To listen to paid episodes in Apple or Spotify, link your Substack subscription via the s settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).

Abstract

UpDoc, a Palo Alto company spun out of Stanford in 2023, announced on June 2 2026 what it called the first FDA-cleared clinical AI platform with a patient-faci LLM, alongside $18M in seed funding and deployments at four major health sys Strip away the press release and the actual regulatory artifact is narrower and fa more interesting: a 510(k) (K253281, cleared Dec 23, 2025) for a prescription SaM that manages basal insulin in adults with type 2 diabetes, cleared as substantiall equivalent to a drug-dose calculator (Hygieia d-Nav, K181916), under product cc NDC, regulation 21 CFR 868.1890. The clinical evidence base traces to a 32-pati randomized trial (MIVA, NCT05081011) published in JAMA Network Open. Thi piece walks the gap between the category-defining narrative and the bounded de that actually got cleared, why the boring regulatory path was the smart one, who funded it (Lilly, Mayo, the ADA, Section 32, Polaris, Pear, Cathay, Oxeon), and w the precedent does and does not unlock for everyone trying to build the next one

Quick hits:

1. FDA cleared a calculator that can talk, not an autonomous doctor.
2. The LLM sits outside a deterministic dosing core.
3. No clinical testing was required for the clearance.
4. A PCCP was authorized, with limits.
5. The strategic cap table tells you who thinks this category is real.

Table of Contents

Two stories, one company

There are two versions of UpDoc circulating right now, and they do not really sc like the same product. The first version is the one that hit the wire this past Jun one with the phrase clinical AI in bold energy, defined as artificial intelligence t delivers care historically requiring a licensed clinician. In that telling, UpDoc ar as the company that did the hard thing responsibly while everyone else raced to the word doctor on a chatbot, and the FDA blessing is the proof. Andy Conrad, t former Verily chief and Section 32 partner, supplied the canonical quote about U not just redefining the category but establishing what it means to do it responsil The CEO, Sharif Vakili, supplied the line about clinical AI being held to the hig standard. The whole thing reads like the opening of a new chapter in medicine.

The second version is the one sitting in the FDA's public database, and it is a go deal more modest. That version is a prescription software device that helps adul

with type 2 diabetes titrate their basal insulin, cleared because it is substantially equivalent to a dosing calculator that has existed for years. Both versions are tru the same time, which is the part worth sitting with. The interesting thing about UpDoc is not that the marketing oversells it, because all health tech marketing oversells. The interesting thing is the specific, deliberate engineering of the gap between what was built and what was claimed, and how cleverly the regulatory strategy threaded a needle that a lot of better-funded companies have face-plant For an audience that has watched a decade of digital health companies confuse a release with a business, the UpDoc clearance is less a milestone and more a case in how to get a large language model across the FDA finish line without pretend does something it does not.

← Previous